MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapeutic agents for the treatment of cancer and autoimmune disorders. Leveraging a proprietary protein engineering platform, the company designs multi-specific antibody constructs and immune-modulating fusion proteins that aim to enhance target selectivity, extend half-life, and improve tissue penetration. MAIA’s pipeline encompasses both oncology and immunology programs, with lead candidates advancing through preclinical and early-stage clinical trials.
The company’s flagship oncology programs feature bispecific antibodies directed at complementary immune checkpoints, engineered to potentiate T-cell responses against solid tumors while minimizing off-target effects. In parallel, MAIA is developing targeted therapies for autoimmune indications, including novel cytokine inhibitors and regulatory T-cell modulators designed to restore immune balance in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These assets are supported by an integrated discovery engine that combines high-throughput screening, computational biology, and translational biomarkers.
Founded in 2017 as a spin-out from leading academic research institutions, MAIA Biotechnology has built its headquarters and primary research facilities in the Greater Boston area, with an additional biomanufacturing site in the San Francisco Bay Area. The company collaborates with academic centers and contract research organizations across North America and Europe to advance its clinical programs. Strategic partnerships include material transfer agreements for cell-based assays and joint research initiatives focused on novel tumor microenvironment targets.
Under the leadership of CEO Dr. Maria J. Alvarez, a veteran of the biotech industry with over two decades of experience in antibody drug development, MAIA’s management team combines expertise in molecular biology, clinical operations, and regulatory affairs. The board of directors includes industry executives and scientific advisors who have guided multiple biologics through regulatory approval. MAIA Biotechnology continues to pursue value-driving milestones in both its oncology and immunology franchises, aiming to address unmet medical needs through precision immunotherapy.
